Theramex announced today that it received decentralized procedure approval in several EU countries and the UK for its Bijuva capsules. Bijuva possesses an indication for continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses, according to a news release. […]
